![Podcast: Beyond the Holding – A Nuanced Look at the Federal Circuit’s Patent Decisions (Episode 5)](https://media2.mofo.com/v3/images/blt5775cc69c999c255/blt0ffd7c8dd700a3ab/627316ea7198441d81b3a56b/10_07_professionalmicrophone_blog_v12.jpg?format=auto&quality=60&width=700)
Morrison & Foerster and the Berkeley Center for Law & Technology (BCLT) have teamed up to present a recurring podcast addressing recent Federal Circuit decisions.
In this episode, Brian Matsui, a partner in Morrison & Foerster’s Appellate + Supreme Court practice and Allison Schmitt, BCLT's Life Sciences project director discuss:
- When do post-marketing tests required by the U.S. Food and Drug Administration (FDA) that lead to the claimed combination not demonstrate obviousness?
- The interplay between reasonable expectation of success and disclosed ranges in prior art.